NuvaRing Contraceptive Device has recently come under scrutiny for potentially causing a higher risk of blood clots than other forms of birth control.
NuvaRing, a hormonal contraceptive made by Organon, has been linked to instances of blood clots, stroke, and other cardiac side effects in women. The NuvaRing injury lawyers at our firm are currently researching the side effects and possible injuries by the use of NuvaRing. We are committed to seeing that Organon is held accountable for marketing this defective contraceptive.
NuvaRing was approved by the U.S. Food and Drug Administration in 2001. Since that time, there have been numerous reports of blood clots, strokes, and pulmonary emboli in women using the contraceptive. The unusually high number of injuries associated with NuvaRing are apparently linked with the high levels of hormones released by the device, an inappropriate dosage on which our lawyers are focusing.
The NuvaRing device is aptly named. It is literally a small plastic ring inserted into the vagina for three weeks to release hormones that prevent pregnancy. While all contraceptives are linked to some degree of cardiac risk, the additional risks of stroke and pulmonary emboli make NuvaRing especially dangerous, and even potentially fatal.
NuvaRing releases two hormones: ethinyl estradiol and etonogestral. The first is a form of estrogen, and the second is an active metabolite of desogestrel, a form of progestin. The daily release of etonogestral is approximately 120 micrograms, a relatively high dose.
At least two studies published in the New England Journal of Medicine in 2003 have confirmed that progestin desogestrel increases the risk of a potentially fatal variety of blood clot known as a venous thromboembolism. This risk is much higher than presented by low-estrogen birth control pills that contain levonorgestrel.
It is believed that the use of the active desogestral metabolite etonogestral in the NuvaRing device could place women in the same high risk category for developing a venous thromboembolism and also subjects them to an enhanced potential for harmful cardiac conditions.
The FDA has been aware of these dangers for some time. In 2007, the consumer advocacy group Public Citizen asked for an FDA ban on oral contraceptives containing desogestral. The group specifically cited the increased risk of strokes, clotting, and cardiovascular problems.
Our lawyers have examined the promotional literature Organon distributes with the device. It claims that NuvaRing releases a low dose of hormones, and that there is a minimal potential for side effects like headaches, nausea, and breast tenderness. We feel these statements are clearly misleading, and do not highlight the more serious circulatory and cardiac dangers linked to the use of the NuvaRing product. Where cardiac side effects are mentioned, the implication is that there is no greater danger presented by NuvaRing than with any oral contraceptive.
Our firm is currently evaluating a slate of these potential lawsuits against Organon. If you or a loved one have suffered from blood clots, strokes or other cardiovascular problems that you suspect were linked to the use of NuvaRing, you could be entitled compensation. Please fill out our online form or call 1-843-839-3377 for a free consultation with a qualified NuvaRing injury lawyer.